Azeliragon ameliorates Alzheimer's disease via the Janus tyrosine kinase and signal transducer and activator of transcription signaling pathway

OBJECTIVES: TTP488, an antagonist of the receptor for advanced glycation end-products, was evaluated as a potential treatment for patients with mild-to-moderate Alzheimer’s disease (AD). However, the mechanism underlying the protective action of TTP488 against AD has not yet been fully explored. MET...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clinics (Sao Paulo)
Asıl Yazarlar: Yang, Lijuan, Liu, Yepei, Wang, Yuanyuan, Li, Junsheng, Liu, Na
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Faculdade de Medicina / USP 2021
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7920406/
https://ncbi.nlm.nih.gov/pubmed/33681944
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6061/clinics/2021/e2348
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller